GT-02287 Shows Promise in Slowing Parkinson's Progression, New Data Suggest

Gain Therapeutics has shared promising preclinical data suggesting that its experimental drug, GT-02287, may slow the progression of Parkinson's disease. In studies using mouse and cell models, the drug improved motor skills, coordination, and daily function, while reducing harmful protein clumps, like alpha-synuclein, that are linked to the disease. GT-02287 is designed to restore the function of GCase, an enzyme that helps break down toxic proteins in the brain. Mutations in the GBA1 gene, which affects GCase production, are the most common genetic risk factor for Parkinson’s. By improving GCase activity, GT-02287 could prevent the buildup of toxic substances and slow disease progression. In tests, the drug not only helped mice with and without GBA1 mutations but also maintained its benefits even after treatment stopped. The study showed that GT-02287 improved both brain cell health and energy production, which are crucial in fighting neurodegeneration. These findings suggest the drug could be a potential therapy for both Parkinson's and other conditions like Alzheimer's disease. The data were presented at the Society for Neuroscience 2024 conference, with researchers optimistic about future trials.